Evidence map›Paper›PMID 37846191›Full record

ArticleThe oncologist2024

Evaluating Oncologists' Practice Patterns and Decision-Making in Locally Advanced or Metastatic Urothelial Carcinoma: The US Physician PARADIGM Study.

Shilpa Gupta, Halley Costantino, Chiemeka Ike, Shaloo Gupta, Abhijeet Bhanegaonkar, Cathy Su, Sheena Thakkar, deMauri S Mackie, Geeta Devgan, Howard M Katzenstein and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The oncologist, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Shilpa GuptaDepartment of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.
Halley CostantinoCerner Enviza, an Oracle company, Kansas City, MO, USA.
Chiemeka IkeEMD Serono, Inc., Rockland, MA, USA, an affiliate of Merck KGaA.
Shaloo GuptaCerner Enviza, an Oracle company, Kansas City, MO, USA.
Abhijeet BhanegaonkarEMD Serono, Inc., Rockland, MA, USA, an affiliate of Merck KGaA.
Cathy SuCerner Enviza, an Oracle company, Kansas City, MO, USA.
Sheena ThakkarPfizer, New York, NY, USA.
deMauri S MackieCerner Enviza, an Oracle company, Kansas City, MO, USA.
Geeta DevganPfizer, New York, NY, USA.
Howard M KatzensteinEMD Serono, Inc., Rockland, MA, USA, an affiliate of Merck KGaA.
Frank X LiuEMD Serono, Inc., Rockland, MA, USA, an affiliate of Merck KGaA.

Funding

EMD Serono, Inc., Rockland, MA, USA 10.13039/100004755
6 · The paper itself

Abstract

backgroundThe treatment landscape for locally advanced/metastatic urothelial carcinoma (la/mUC) has evolved. This study examined US prescribing patterns and clinical decision-making for first-line (1L) and first-line maintenance (1LM) treatment. MATERIALS AND

methodsUS-based oncologists (N = 150) completed an online survey on patient demographics, practice patterns, and important factors considered in 1L/1LM selection. Multivariable logistic regression was used to assess factors associated with more vs less frequent 1L/1LM prescribing.

resultsPhysician reports estimated that 23% of patients with la/mUC had not received any systemic therapy in the previous 6 months; however, 46% received 1L, 32% received second-line, and 22% received subsequent-line systemic treatments. Of patients who were receiving 1L treatment, 72% were estimated to be receiving 1L platinum-based chemotherapy. Around 69% of patients eligible for 1LM received the treatment. Physicians categorized as frequent prescribers reported overall survival (OS), disease control rate (DCR), and rate of grade 3/4 adverse events (AEs) as factors associated with 1L treatment selection (all P < .05). OS, rate of grade 3/4 immune-mediated AEs, and inclusion in institutional guidelines were reported as attributes used in 1LM treatment selection (all P < .05). Multivariable analysis revealed OS, DCR, and rate of grade 3/4 AEs as important factors in oncologists' 1L treatment selection; academic practice setting and use of Response Evaluation Criteria in Solid Tumors version 1.1 were associated with 1LM use (all P < .05).

conclusionOS and AEs were found to be relevant factors associated with offering 1L and 1LM treatment. Variability exists in physicians' decision-making in the real-world setting for la/mUC.

Indexed as

Carcinoma, Transitional CellOncologistsPhysiciansUrinary Bladder NeoplasmsHumansResponse Evaluation Criteria in Solid Tumorschemotherapydecision-makingimmune checkpoint inhibitorsystemic therapyurinary bladder cancer

Identifiers

PMID37846191
PMCPMC10911905

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.